As we have already mentioned, Gal-3 regulates macrophage differentiation in NSCLC [90], and treatment with GB1107 (a Gal-3 inhibitor) increased tumor M1 macrophage polarization and CD8+ T-cell tumor infiltration. The gene discussed is CD8A; the disease is neoplasm.